الفهرس 
Evaluation of kallistatin as a biomarker in chronic hepatitis C patients
ABSTRACTOnly 14 pages are availabe for public view
 |  | from | 196 |  |  |
| | | from | 196 | | |
Abstract
Hepatitis C virus infection is a common health problem in Egypt. Liver biopsy (LB) is the gold standard for providing useful information on the liver disease progression. Due to the limitations, and risks of biopsy, as well as the improvements of the diagnostic accuracy of new noninvasive markers, numerous studies strongly suggest that liver biopsy should no longer be considered obligatory as a first line mode of evaluation in some chronic liver diseases. Noninvasive biomarkers including kallistatin were measured in serum samples of HCV induced chronic liver disease patients by ELISA and gene expression of SERPINA4 was detected by qRT-PCR. We tried to develop noninvasive diagnosis that can be applied to patients who either have contraindications or refuse liver biopsy for the management of their HCV infection